3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
137
Breast Neoplasms
10
Neoplasm Metastasis
8
Neoplasms
5
Bulbo-Spinal Atrophy, X-Linked
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
2
Prostate Adenocarcinoma
2
Osteoporosis
2
Lower Urinary Tract Symptoms
2
Hirsutism
2
Thrombocytosis
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Sexual Dysfunction, Physiological
1
Recurrence
1
Primary Myelofibrosis
1
Primary Dysautonomias
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Paget Disease, Extramammary
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Castrate Metastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
11
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
Radiotherapy
5
dodecyl maltoside
4
apaziquone
4
tislelizumab
3
Cystoscopy
3
ALT-803
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
bicalutamide
×
Clear all
NCT05327647
2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2
Recruiting
160 enrolled